KDR and nonpapillary renal cell carcinoma: Although the advent of immunotherapy with checkpoint inhibitors and sequential use of targeted agents has brought a promising treatment landscape for advanced ccRCC, it is urgent to elucidate the precise mechanisms of resistance to VEGFR-TKIs (Rini and Atkins, 2009).